XML 30 R45.htm IDEA: XBRL DOCUMENT v3.19.3
Quarterly Financial Data (Unaudited) (Tables)
 12 Months Ended
Sep. 27, 2019
Quarterly Financial Information Disclosure [Abstract]  
Schedule of Quarterly Financial Data
 
 
Fiscal Year 2019
(In millions, except per share amounts)
 
First
Quarter (1)
 
Second
Quarter
 
Third
Quarter (2)
 
Fourth
Quarter (3)
 
Total
Year
Total revenues
 
$
741.0

 
$
779.4

 
$
825.8

 
$
878.9

 
$
3,225.1

Gross margin
 
$
316.1

 
$
318.2

 
$
351.4

 
$
384.6

 
$
1,370.3

Net earnings
 
$
103.9

 
$
88.4

 
$
29.5

 
$
70.4

 
$
292.2

Net earnings attributable to Varian
 
$
103.2

 
$
88.6

 
$
29.4

 
$
70.7

 
$
291.9

 
 
 
 
 
 
 
 
 
 
 
Net earnings per share - basic
 
$
1.13

 
$
0.97

 
$
0.32

 
$
0.78

 
$
3.21

Net earnings per share - diluted
 
$
1.12

 
$
0.96

 
$
0.32

 
$
0.77

 
$
3.18

 
 
 
 
 
 
 
 
 
 
 
 
 
Fiscal Year 2018
(In millions, except per share amounts)
 
First
Quarter (4)
 
Second
Quarter (5)
 
Third
Quarter (6)
 
Fourth
Quarter (7)
 
Total
Year
Total revenues
 
$
678.5

 
$
729.9

 
$
709.1

 
$
801.6

 
$
2,919.1

Gross margin
 
$
302.8

 
$
318.5

 
$
313.6

 
$
338.7

 
$
1,273.6

Net earnings (loss)
 
$
(112.2
)
 
$
73.2

 
$
72.5

 
$
116.8

 
$
150.3

Net earnings attributable to Varian
 
$
(112.3
)
 
$
73.2

 
$
72.6

 
$
116.4

 
$
149.9

 
 
 
 
 
 
 
 
 
 
 
Net earnings (loss) per share - basic
 
$
(1.22
)
 
$
0.80

 
$
0.79

 
$
1.27

 
$
1.64

Net earnings (loss) per share - diluted
 
$
(1.22
)
 
$
0.79

 
$
0.79

 
$
1.26

 
$
1.62



(1) 
In the first quarter of fiscal year 2019, net earnings includes a $22.0 million gain on the sale of our investment in Augmenix.
(2) 
In the third quarter of fiscal year 2019, net earnings includes a $50.5 million goodwill impairment charge related to the Company's Proton Solutions business and a $20.8 million charge associated with the write-off of in-process R&D related to an acquisition.
(3) 
In the fourth quarter of fiscal year 2019, net earnings includes an $18.6 million charge to acquisition-related expenses due to an increase to the fair value of contingent consideration related to an acquisition.
(4) 
In the first quarter of fiscal year 2018, net earnings includes a $207.1 million income tax expense related to the tax effect of a change in law related to the Act.
(5) 
In the second quarter of fiscal year 2018, net earnings includes a $16.4 million loss related to hedging the anticipated Australian dollar purchase price for Sirtex and an $11.1 million impairment charge related to our MPTC subordinated loan.
(6) 
In the third quarter of fiscal year 2018, net earnings includes a $13.3 million loss related to hedging the anticipated Australian dollar purchase price of the Sirtex acquisition, an $11.0 million impairment charge related to our MPTC subordinated loan, acquisition costs of $8.4 million, partially offset by the net $9.0 million breakup fee received from Sirtex in connection with the termination of the acquisition.
(7) 
In the fourth quarter of fiscal year 2018, net earnings includes a $8.0 million benefit to income tax expense due to the partial release of a valuation allowance as the result of an acquisition and a $7.1 million benefit to income tax expense related to the Act.